Showing 4971-4980 of 9403 results for "".
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. <
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop
- IFPA Launches All the Colors We Are to Call Attention to Diversity in Psoriatic Diseaseshttps://practicaldermatology.com/news/ifpa-launches-all-the-colors-we-are-to-call-attention-to-diversity-in-psoriatic-diseases/2461419/IFPA is launching a new image library that raises awareness of diversity in psoriatic disease. IFPA is the global organization representing all people with psoriatic disease,. Go to any image database, and type “psoriasis” in the search bar. The results? Invariably
- Positive Results for Dermavant's Vtama in Pediatric Maximal Usage Study in Atopic Dermatitishttps://practicaldermatology.com/news/positive-results-for-dermavants-vtama-in-pediatric-maximal-usage-study-in-atopic-dermatitis/2461418/Dermavant Sciences shared positive results from its maximal usage study of Vtama (tapinarof) cream 1% in children down to age 2 years old with extensive burden of atopic dermatitis. “We are delighted with the results from our maximal usage study of Vtama cream 1% in atopic dermati
- Meet Crown’s ProGen PRP Eclipsehttps://practicaldermatology.com/news/meet-crowns-progen-prp-eclipse/2461417/Crown Aesthetics completed the rebranding of ProGen PRP Advantage, now renamed ProGen PRP Eclipse. ProGen PRP Eclipse is a one-spin system that features 15 mL and 30 mL tubes, yielding 7-15 mL of Platelet Rich Plasma. "Crown's commitment to best-in-class service
- Cutera's AviClear Now Broadly Available to US Physicians and Practitionershttps://practicaldermatology.com/news/cuteras-aviclear-now-broadly-available-to-us-physicians-and-practitioners/2461416/Cutera, Inc.’s AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both U.S. Food and Drug Administration cleared and Health Canada approved for
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis 
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is publish